Compare Repligen Corporation Common Stock (RGEN) vs SK Hynix (SKHY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs SK Hynix — how do they compare? Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B), while SK Hynix trades at $137.16 (market cap $768.83B). The key difference: SK Hynix is far larger — about 69× Repligen Corporation Common Stock's market cap, and SK Hynix pays a 0.07% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and SK Hynix for 12 Days on average.
| RGEN | SKHY | |
|---|---|---|
Market Cap | $11.14B | $768.83B |
Volume | 1,259,263 | 21,786,972 |
Sector | Health | Technology |
52-Week High | $194.57 | $198.63 |
52-Week Low | $102.87 | $126.79 |
Typical Hold Time | 0 Days | 12 Days |
Enterprise Value | $11.02B | $718.72B |
Dividend Yield | — | 0.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
SKHY trades at $157.06, down 3.15% amid a sector-wide tech selloff driven by Fed rate hike concerns and competitive threats from Chinese chipmaker CXMT. The stock shows strong fundamentals with a P/E of 9.27, net income margin of 85.62%, and consistent earnings beats. Technical indicators are bearish with moving averages signaling selling pressure, though oscillators suggest potential oversold conditions. Recent news highlights AI memory demand growth but also increased competition risks.
Despite near-term volatility, SKHY maintains robust profitability and analyst consensus remains bullish with a $242 price target representing 54% upside. Key risks include Chinese competition and macroeconomic pressures, but the company's leadership in AI memory and strong financial metrics support long-term growth potential for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About SK Hynix
SK hynix is a South Korean semiconductor company that manufactures memory products, including DRAM and NAND flash. Its high-bandwidth memory (HBM) products are designed for high-performance computing and AI applications.
Read more on SKHY →
